Revive Therapeutics (RVV.C) intends to advance its product pipeline to human clinical studies in regions where its products have already acquired regulatory approval and are approved for sale.
Trust me, there’s nothing I’d like more, as the publisher of a financial markets-focused media outlet, than to tell you all it’s time to buy back in on these ailing markets. I’ve got clients who’d reward me well if I were to convince you that it’d be a good idea to buy their stock in the middle of a stock slide. I’ve got employees that I’m still paying and not laying off that are ready to do their thing and share good investing opportunities with you all, especially at a time when you’re all at home looking for information.
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.
Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who'd listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O'Leary were on board. Champignon Brands (SHRM.C) zoomed 40% to $0.33 on a lot smaller market awareness spend byt a handy ticker, Roadman Investments (LITT.V) was up 30% to $0.065 being sucked along in the other two companies' wake, and Revive Therapeutics (RVV.C) was up 81% to $0.10 on ripples caused by the rest.